Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System
SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise
Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure
Merck signs $3bn deal for Kate Bingham-backed eye disease biotechRead More
SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion
Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation
QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
- 6 July 2020Portfolio NewsAVROBIO Announces New Patients Dosed in Gaucher Disease and Cystinosis Clinical Trials
- 23 June 2020Portfolio NewsSV Health Investors notes Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics
- 23 June 2020Portfolio NewsBicycle Therapeutics Appoints Sir Keith Peters as Chairman of Its Scientific Advisory Board
- 23 June 2020Portfolio NewsAlchemab Therapeutics among three companies that comprise the inaugural funding cycle of Illumina Accelerator Cambridge UK
- 22 June 2020Portfolio NewsDeciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
- 17 June 2020Portfolio NewsXilio Therapeutics Appoints Daniel S. Lynch as Chair of Board of Directors
- 11 June 2020Portfolio NewsX4 Pharmaceuticals Promotes Renato Skerlj, Ph.D., to Chief Scientific Officer
- 8 June 2020Portfolio NewsDeciphera Announces Publication of the INVICTUS Pivotal Phase 3 Study of QINLOCK™ (ripretinib) in The Lancet Oncology
- 3 June 2020Portfolio NewsErvaxx rebrands as Enara Bio to reflect a broader emphasis on the discovery and development of novel TCR‐based cancer immunotherapies
- 29 May 2020Portfolio NewsDeciphera Pharmaceuticals Announces Presentations of Positive Patient Reported Outcomes Results from INVICTUS Phase 3 Study of QINLOCKTM (ripretinib) in Patients with Fourth-Line Advanced GIST at the ASCO 2020 Virtual Scientific Program
- 21 May 2020Portfolio NewsSutro Biopharma Expands Senior Management with the Additions of Vice President of Clinical Development and Vice President of Finance and Controller
- 15 May 2020Portfolio NewsFDA Grants Full Approval of Deciphera Pharmaceuticals’ QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor